Boundaries of BPCIA Patent Exchange Get Tested in Court
New cases provide insights into how the Biologics Price Competition and Innovation Act will govern future patent disputes over biosimilar applications.
May 15, 2015 at 03:34 PM
9 minute read
Sheila Swaroop
In 2010, Congress enacted the Biologics Price Competition and Innovation Act, which created a new pathway for regulatory approval in the United States of follow-on biologics that are “biosimilar” to or “interchangeable” with previously approved biologics. This pathway has generated tremendous interest in the biopharmaceutical industry because of the market opportunities for biologic therapies, and there have been many public announcements of biosimilar development programs and partnerships from companies such as Amgen, Baxter, Merck, and Pfizer.
Of particular significance for IP practitioners was the BPCIA's establishment of a unique pre-litigation patent exchange between a biosimilar applicant seeking FDA approval under the BPCIA and the Reference Product Sponsor of the previously approved biologic. In this patent exchange, the parties disclose information on patents owned or licensed by the RPS that could be infringed by the biosimilar applicant, and then negotiate over which patents will be litigated prior to and after commercial launch of the biosimilar product.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 2The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 3First Lawsuit Filed Alleging Contraceptive Depo-Provera Caused Brain Tumor
- 4The 'Biden Effect' on Senior Attorneys: Should I Stay or Should I Go?
- 5Elder Litigators Confront Tough Questions in Last Act of Careers
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250